# Core Laboratories Inc. (CLB) fundamentals

Data as of 2026-11-04. NYSE, United States. Sector: Energy / Oilfield Services & Equipment. Price $9.77, market value $448 million.

## Valuation
- **P/E (trailing): 28.7×** (5-yr avg 34.9×, 3-yr avg 24.8×). Core Laboratories Inc. trades at 28.7× trailing earnings, close to its own five-year average of 34.9×. The Energy median in the September 2026 study was 16.8×. Forward P/E is 14.2×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 0.9×**. Each dollar of revenue is priced at 0.9×, a low multiple typical of thin-margin businesses or out-of-favour stocks.
- **Price / book: 1.6×**. The shares trade at 1.6× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 9.9×**. Enterprise value is 9.9× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 2.3%** (5-yr avg 2.9%). Free cash flow equals 2.3% of the market value, in line with its five-year average of 2.9%.
- **Earnings yield: 3.5%**. The inverse of the P/E: 3.5% of the price is earned each year.

## Profitability
- **Operating margin: 7.5%**. 7.5% of revenue is left after running the business.
- **Net margin: 5.6%**. 5.6% of each dollar of sales reaches the bottom line.
- **Return on equity: 11.2%**. 11.2% on shareholders' equity is solid.
- **Return on invested capital: 8.7%**. Return on all capital, debt included, is 8.7%.
- **Return on assets: 2.7%**. Each dollar of assets produces 2.7% of profit.

## Growth
- **Revenue growth (1 yr): 0.5%** (3-yr 2.4%/yr). Revenue grew 0.5% over the last year.
- **EPS growth (1 yr): -4.5%** (3-yr 14.5%/yr). Earnings per share fell 4.5%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): 20.5%/yr**. Free cash flow has compounded at 20.5% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.41**. Debt is 0.41 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 1.6×**. It would take 1.6 years of operating earnings to repay net borrowings, within the comfortable range.
- **Current ratio: 2.02** (quick 2.02). Current assets cover the next year's liabilities 2.02 times.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 0.41%** ($0.04 per share, trailing). Core Laboratories Inc. yields 0.41%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 6%** (18% of free cash flow). 6% of earnings goes out as dividends, leaving room to keep raising it.
- **Consecutive years of increases: 4**. 4 straight years of increases.
- **Dividend growth (5 yr): -32.2%/yr** (1-yr 0.0%). The dividend has not grown over five years.

## Analyst view
- **Analyst consensus: buy** (3 analysts). 3 analysts cover Core Laboratories Inc.; the consensus is buy, with an average price target of $15.00 (+54% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -35.9%** (YTD -36.3%, 3-mo -4.9%). The shares are down 35.9% over twelve months including dividends.
- **From 52-week high: -52.0%** (7.0% above the low). Trading 52% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 47**. An RSI of 47 is neutral.
- **Beta (1 yr): 0.99** (volatility 46%). Beta of 0.99 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CLB · Page: https://foliofundamentals.com/stocks/clb

Not investment advice.